ADMiER reduces the time required to diagnose dry eye disease from an estimated 18 minutes of chair-time to just three minutes. Help us enhance clinical outcomes for patients with more accurate disease characterisation through licensing.
The innovation
An in-vitro diagnostic device to identify and subtype dry eye disease from a microlitre tear droplet. ADMiER is simple to use, rapid, inexpensive and highly accurate. Ninety-two per cent of patients tested with ADMiER preferred it to standard clinical tests.
Market need
Dry eye affects one in five adults. It’s the most common indication for medical eye care in developed countries, with societal costs estimated at $US5 billion a year in the US alone.
Eye care clinicians struggle to diagnose dry eye disease with current clinical methods. As a result, up to 80 per cent of diagnoses will be inaccurate and lacking essential details about the dry eye disease subtype to inform treatment.
Innovation status
This technology is predicted to have a major impact on enhanced clinical diagnostics for dry eye in ophthalmic practice. It provides optometrists a novel approach for assessing teal film integrity for clinical diagnosis and monitoring of dry eye disease.
Contact
Dr Anna Malinovitch
anna.malinovitch@unimelb.edu.au
Flyer
Download flyer for more information (PDF, 524 KB)
Keep reading
-
Negotiating a licence with the University
By licensing the University of Melbourne’s intellectual property (IP) and technologies, you can harness research discoveries to solve business challenges.
-
Our IP principles
Our Intellectual Property (IP) management principles make it easier to collaborate with us.
-
Investing in University startups
Find out about new ways to invest in University startups
-
Contact
From developing an idea to finding startup funding, the University of Melbourne’s team of experts can help.